Spiral Therapeutics to Participate at the 2024 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 5, 2024 — Spiral Therapeutics, Inc. (Spiral), a pharmaceutical company dedicated to developing advanced treatments for balance disorders and hearing loss, today announced that it will participate in the 2024 Wedbush PacGrow Healthcare Conference taking place August 13-14, 2024, in New York, NY. Hugo Peris, Spiral’s Founder and CEO, will participate in a panel focused […]
Spiral Therapeutics Receives Hearing Technology Innovator Award
SOUTH SAN FRANCISCO, Calif., August 30, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced today that it has been recognized for its innovative Drug Delivery Platform in the fourth annual Hearing Technology Innovator Awards™. The annual awards program by Hearing Health & Technology Matters (HHTM) acknowledges technological innovation and […]
Spiral Therapeutics Announces CEO’s Participation at the 3rd Inner Ear Disorders Therapeutics Summit in Boston, MA
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company delivering therapies for inner ear disorders, is proud to announce the participation of its Chief Executive Officer, Hugo Peris, at the forthcoming 3rd Inner Ear Disorders Therapeutics Summit. The event is scheduled to take place from August 29-31, 2023, in […]
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
SOUTH SAN FRANCISCO, Calif., March 29, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc. (“Otonomy”), following the stockholder approval of Otonomy’s dissolution. The transaction includes preclinical and clinical data related to OTO-104 (OTIVIDEX), a sustained-exposure […]